Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory
therapy which involves separation of the patient's leucocyte‐rich plasma, followed by ex vivo …

Extracorporeal photopheresis (ECP) is a combination of leukapheresis and photodynamic
therapy in which blood is treated with photoactivable drugs which are then activated with …

This synopsis reviews recent developments in dermatological phototherapy. UVA1
phototherapy (340-400 nm) is effective in the treatment of inflammatory skin diseases such …

Edelson et al. first reported the use of extracorporeal photopheresis (ECP) to treat cutaneous
T‐cell lymphoma (CTCL) in 1987, and since then several studies reporting response rates …

Extracorporeal photopheresis (ECP) is a technique that was developed> 20 years ago to
treat erythrodermic cutaneous T‐cell lymphoma (CTCL). The technique involves removal of …

Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …

Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory
therapy based upon pheresis of light‐sensitive cells. Whole blood is removed from patients …

Photopheresis or extracorporeal photochemotherapy (ECP) is an immunomodulating
procedure that has been available for the treatment of cutaneous T‐cell lymphoma (CTCL) …

Cutaneous T-cell lymphoma is the overall name for a group of malignancies in which
malignant T-lymphocytes localize at the skin. Of the current 20 recognized subtypes of the …

Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-
methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological …